Denis Chem Lab Q1 FY27 Results: Revenue Flat at Rs 43 Crore, PAT Declines 17% to Rs 2 Crore

Denis Chem Lab Q1 FY27 results showed the standalone pharmaceutical company reporting Rs 43 crore revenue, up just 1.67% from Rs 43 crore in Q1 FY26. Despite revenue stability, gross profit fell 28% from Rs 3 crore to Rs 2 crore — indicating raw material or API cost inflation that was not recovered through pharmaceutical selling prices.

The Denis Chem Lab Q1 FY27 results showed gross margin contracting from approximately 7% (Rs 3 Cr on Rs 43 Cr) to 4.7% (Rs 2 Cr on Rs 43 Cr) on flat revenue — a 2.3 percentage point margin compression from pharmaceutical ingredient cost increases.

Click Here – Get Free Investment Predictions

Denis Chem Lab Q1 FY27 Financial Highlights

Metric	Q1 FY27 (Rs Crore)	Q1 FY26 (Rs Crore)	YoY Change
Revenue	43.00	43.00	+1.67%
Gross Profit	2.00	3.00	-28.08%
Net Profit / PAT	2.00	2.00	-17.37%

Denis Chem Lab Q1 FY27 Performance Analysis

Use the Univest Screener to track Denis Chem Lab live financials and Q1 FY27 results

Denis Chem Lab Q1 FY27 results show flat revenue alongside 28% gross profit decline — the defining challenge of API and pharmaceutical ingredient cost inflation in a market where selling prices cannot be easily increased in competitive generic segments.

Gross margin falling from 7% to 4.7% in Q1 FY27 results on flat revenue reflects the same challenge facing many pharmaceutical companies in Q1 FY27 — raw material inflation without corresponding realisation improvement.

PAT declining 17% to Rs 2 crore from Rs 2 crore on lower gross profit suggests the company has limited non-operational income to offset the margin deterioration, unlike some peers.

Denis Chem Lab needs either API cost relief or pharmaceutical selling price improvement to restore gross margins from Q1 FY27 results levels.

Key Business Factors in Q1 FY27

API Cost Inflation

Pharmaceutical ingredient costs rising in Q1 FY27 compressed gross margins from 7% to 4.7% on flat revenue.

Generic Market Pricing

Competitive generic pharma market limits selling price increases when input costs rise.

Revenue Quality

Flat revenue at Rs 43 crore with lower margins means Q1 FY27 results represent lower earnings quality than Q1 FY26.

Dividend Details

Denis Chem Lab has not declared a dividend for Q1 FY27.

FY27 Outlook

The FY27 outlook depends on API cost moderation and revenue growth. If pharmaceutical ingredient prices normalise from Q1 FY27 levels, gross margins should recover toward 7%.

Any new product launches or institutional market entry would support both revenue growth and margin improvement.

Denis Chem Lab Stock Performance

Download the Univest iOS App or Univest Android App to track Denis Chem Lab share price live and stay updated on quarterly results.

Denis Chem Lab shares traded at Rs 70.63 on August 13, 2026, down 1.98%. Market reflecting the margin compression visible in Q1 FY27 results.

Key Risks

Sustained API Inflation

Continued pharmaceutical ingredient cost elevation keeps gross margins at 4.7% — further PAT pressure if revenue growth is also absent.

Generic Competition

India's generic market is intensely competitive — price competition limits the ability to pass through input cost increases.

Revenue Stagnation

Flat revenue growth of 1.67% in Q1 FY27 means the company needs new product or market initiatives for growth.

Conclusion

Denis Chem Lab Q1 FY27 results show flat revenue at Rs 43 crore alongside 17% PAT decline to Rs 2 crore as gross margins compressed from API cost inflation — stable volume but weaker unit economics.

API cost management and revenue growth are the priorities. Consult a SEBI-registered advisor.

Frequently Asked Questions on Denis Chem Lab Q1 FY27 Results

When announced?

Ans. August 13, 2026, standalone.

Revenue?

Ans. Rs 43 crore, essentially flat +1.67%.

PAT?

Ans. Rs 2 crore, down 17.37%.

Why did gross profit fall 28% on flat revenue?

Ans. API and pharmaceutical ingredient cost inflation compressed gross margins from 7% to 4.7% on unchanged revenue.

Dividend?

Ans. No dividend for Q1 FY27.

Outlook?

Ans. Depends on API cost moderation and new product growth initiatives.

Investment?

Ans. Margin compression in pharma manufacturing. Monitor API costs. Consult a SEBI-registered advisor.